Fortrea Highlights China’s Growing Role in Rare Disease Trials
Fortrea highlighted China’s growing role in clinical trials for rare diseases.
Related stories
Shanghai Jinjiang Shipping Q3 Net Profit Rises 21.8% Y/Y
M impact | EQUITY | Oct 29, 2026, 01:29 PM UTC
Altria Reports Q3 Revenue of $5.44 Billion, Up 3.6%
Altria said revenue rose 3.6% year on year to $5.44 billion. Non-GAAP profit was $1.52 per share, 0.9% above analysts’ consensus estimates.
M impact | EQUITY | Oct 29, 2026, 01:28 PM UTC
Brigade Enterprises Quarterly Profit Rises on Residential Demand
Brigade Enterprises reported higher quarterly profit, citing strong residential demand.
M impact | EQUITY | Oct 29, 2026, 01:28 PM UTC
A. O. Smith Reports Q3 Adjusted Earnings, Revises 2026 EPS Guidance
A. O. Smith reported Q3 adjusted earnings and revised full-year 2026 adjusted EPS guidance to exclude its China business. The headline also reports a drop in net sales but gives no
M impact | EQUITY | Oct 29, 2026, 01:28 PM UTC
IndiGo Reports Rs 1,879 Crore Q2 Loss as Fuel Costs, Rupee Weigh
InterGlobe Aviation reported a consolidated net loss of Rs 1,879.1 crore for the July-September quarter of FY27, despite strong revenue growth.
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Kunlun Tech Reports Q3 Net Loss of 1.1 Billion Yuan
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC